Experimental CAR-T therapy targets tough T-Cell cancers in new trial
NCT ID NCT07188610
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 3 times
Summary
This Phase 2 trial tests a single infusion of PA3-17, a CAR-T cell therapy that targets CD7 on cancer cells, in 100 adults with relapsed or refractory T-lymphoblastic leukemia or lymphoma. Participants receive the treatment after a short chemotherapy prep, and researchers will monitor how well it works and any side effects for up to 24 months. The main goal is to see how many patients achieve a complete or partial response within three months.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- PA3-17 injection (a type of CAR-T cell therapy that targets CD7 on cancer cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat T-cell leukemia or lymphoma who have run out of standard therapies.
- What could go wrong
- This is a Phase 2 trial with only 100 participants, so results are still early. CAR-T therapies can cause serious side effects like cytokine release syndrome or nervous system problems, and the cancer may still return.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2025
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age and Gender: ≥18 years old (inclusive), regardless of gender. 2. Survival Expectancy: ≥3 months. 3. Performance Status: ECOG score 0-1. 4. Diagnosis: Confirmed acute T-cell lymphoblastic leukemia/lymphoma (T-ALL/LBL) according to the WHO fifth edition of the "Classification of Hematopoietic and Lymphoid Tumors," including early T-cell precursor (ETP). 5. Recurrent or Refractory Disease: Subjects with recurrent/refractory T-ALL/LBL (including ETP-ALL/LBL). 6. Screening: Abnormal cells CD7 expression positive. 7. Lesion Assessment: If the subject has only extramedullary lesions, they must have evaluable lesions. 8. Meet the requirements of liver, kidney, heart, and lung functions. 9. No Severe Mental Disorders. 10. Informed Consent: Ability to understand the trial and signed informed consent form. Exclusion Criteria: 1. Known to have active or uncontrolled autoimmune diseases; 2. Presence of GvHD; 3. History of malignant tumors other than T-ALL/LBL within the past 5 years, except for adequately treated cervical intraepithelial neoplasia, basal cell or squamous cell skin cancer, locally treated prostate cancer, and ductal carcinoma in situ of the breast after radical surgery; 4. Positive test results for hepatitis B, hepatitis C, syphilis, etc.; 5. Severe heart disease; 6. Unstable systemic diseases as judged by the investigator; 7. Presence of active infection or uncontrollable infection requiring systemic treatment; 8. Pregnant or breastfeeding women, and female subjects planning to conceive within 2 years after cell infusion, or male subjects whose partners plan to conceive within 2 years after cell infusion; 9. Subjects who have received CAR-T therapy or other gene-modified cell therapy before screening; 10. Participation in other clinical studies within 1 month before screening (end date of the last application of unapproved innovative drugs); 11. Evidence of central nervous system involvement at the time of subject screening; 12. Situations judged by the investigator as not suitable for cell preparation; 13. Other circumstances deemed unsuitable for enrollment by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD7-positive relapsed/refractory T lymphoblastic leukemia/lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
16 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Facility Name: Guangdong Provincial People's Hospital
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510080, China
-
Henan Cancer Hospital
RECRUITINGZhengzhou, Henan, 450000, China
-
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
RECRUITINGTianjin, Tianjin Municipality, 300000, China
-
Jiangsu Province Hospital
RECRUITINGNanjing, Jiangsu, 210000, China
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, 100000, China
-
Sun Yat-sen University Cancer Center (SYSUCC)
RECRUITINGGuangzhou, Guangdong, 510000, China
-
The Affiliated Hospital of Xuzhou Medical University
RECRUITINGXuzhou, Jiangsu, 221000, China
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, 215000, China
-
The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital)
RECRUITINGHefei, Anhui, 230000, China
-
The First Affiliated Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, 450052, China
-
The First Affiliated Hospital, Zhejiang University School of Medicine
NOT_YET_RECRUITINGHangzhou, Zhejiang, 310000, China
-
The First Hospital of Harbin
NOT_YET_RECRUITINGHarbin, Heilongjiang, 150000, China
-
Tongji Hospital, Tongji University
RECRUITINGShanghai, Shanghai Municipality, 200000, China
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430000, China
-
West China Hospital, Sichuan University (WCHSU)
RECRUITINGChengdu, Sichuan, 610000, China